Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Schrodinger, Inc. - Common Stock (NQ: SDGR )

24.85 +0.42 (+1.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,585,058
Open 24.84
Bid (Size) 24.72 (5)
Ask (Size) 25.50 (10)
Prev. Close 24.43
Today's Range 24.62 - 25.80
52wk Range 16.67 - 33.63
Shares Outstanding 62,027,061
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26
From Schrödinger
Via Business Wire
AI Pharma: 2 Paths to AI-Powered Drug Investment
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+21.81%
+21.81%
1 Month
+32.96%
+32.96%
3 Month
+36.31%
+36.31%
6 Month
+23.14%
+23.14%
1 Year
-23.54%
-23.54%

More News

Read More
Seagate Posts Upbeat Earnings, Joins Netflix, Travelers, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger Broadens and Accelerates Predictive Toxicology Initiative
From Schrödinger
Via Business Wire
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
Via Benzinga
Schrödinger Reports Third Quarter 2024 Financial Results
From Schrödinger
Via Business Wire
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
From Schrödinger
Via Business Wire
Schrödinger to Present at Jefferies London Healthcare Conference
From Schrödinger
Via Business Wire
Schrödinger to Announce Third Quarter 2024 Financial Results on November 12
From Schrödinger
Via Business Wire
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
Via Talk Markets
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
Via Talk Markets
Topics Economy
Exposures Economy
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
Via Talk Markets
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.